Mission Statement, Vision, & Core Values of Regeneron Pharmaceuticals, Inc. (REGN)

Have you ever wondered what drives a leading biotechnology company like Regeneron? With a remarkable $14.20 billion in revenue for 2024, their mission, vision, and core values clearly play a significant role in their success.

What exactly are the guiding principles behind their life-transforming medicines? How does Regeneron's commitment to science translate into real-world impact for patients?

Let's delve into the core of Regeneron to uncover the mission, vision, and values that shape their groundbreaking work in the biotechnology industry.

Regeneron Pharmaceuticals, Inc. (REGN) An Overview of

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious diseases. Founded in 1988, Regeneron has consistently pushed the boundaries of scientific innovation to address unmet medical needs. As of April 2025, Regeneron continues to be a major player in the biopharmaceutical industry, driven by its dedication to science and its commitment to improving patient outcomes. To delve deeper into the company's origins and evolution, explore Regeneron Pharmaceuticals, Inc. (REGN): History, Ownership, Mission, How It Works & Makes Money.

Regeneron's diverse portfolio includes:

• Eylea (aflibercept): For the treatment of wet age-related macular degeneration and other eye conditions.
• Dupixent (dupilumab): Targeting atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
• Libtayo (cemiplimab): An immunotherapy for certain types of skin cancer.
• REGEN-COV (casirivimab and imdevimab): A combination antibody therapy for COVID-19 (though its use has been impacted by viral variants).

These products reflect Regeneron's strength in therapeutic areas, with a focus on immunology, ophthalmology, and oncology.

Regeneron's financial performance in recent years has been robust, marked by significant revenue growth driven primarily by its key products. In the 2024 fiscal year, Regeneron reported record-breaking revenue, largely fueled by sales of Eylea and Dupixent. According to the 2024 Q4 report, total revenue increased to $13.12 billion. This growth is attributed to increased demand and market penetration, especially for Dupixent, which saw global sales increase by 33% to $9.27 billion. Eylea contributed significantly with U.S. net product sales of $5.88 billion. These figures highlight Regeneron's successful commercial strategy and its ability to capitalize on market opportunities.

Regeneron's success extends beyond its financial achievements. The company's innovative research and development programs have led to a robust pipeline of potential new therapies. As a leader in the biopharmaceutical industry, Regeneron stands out due to its:

• Commitment to scientific innovation: Investing heavily in R&D to discover and develop new medicines.
• Strategic partnerships: Collaborating with other companies and research institutions to expand its capabilities and reach.
• Strong commercial execution: Effectively bringing its products to market and driving sales growth.

Want to know more about why Regeneron is a leader in the industry? Read on to discover the mission, vision, and core values that drive its success.

Regeneron Pharmaceuticals, Inc. (REGN) Mission Statement

Regeneron Pharmaceuticals, Inc. operates as a leading biotechnology company focused on inventing, developing, manufacturing, and commercializing medicines for serious medical conditions. Breaking Down Regeneron Pharmaceuticals, Inc. (REGN) Financial Health: Key Insights for Investors

The company's mission statement is: 'To use the power of science to bring new medicines to patients … over and over again.'

This mission is achieved through a commitment to translating science into effective medicines, resulting in multiple FDA-approved treatments and a robust pipeline of innovative drugs and technologies. The company's medicines are designed to help people with a wide range of conditions, including eye diseases, heart conditions, allergic and inflammatory diseases, chronic pain, cancer, and rare conditions.

Regeneron's mission statement embodies three core components:

• Science-Driven Innovation: The company places a strong emphasis on scientific inquiry and cutting-edge technologies to drive the discovery and development of new medicines.
• Patient-Centric Approach: Regeneron is dedicated to addressing serious medical conditions and improving the lives of patients through its innovative treatments.
• Sustainable Impact: The mission reflects a commitment to continuously bringing new medicines to patients, ensuring a lasting and positive impact on healthcare.

Vision Statement

Regeneron's vision statement reinforces its dedication to translating scientific advancements into tangible medical solutions. It underscores the company's commitment to growth through innovation and the development of new treatments for those in need. This vision is supported by a corporate culture that values diversity, scientific curiosity, and the empowerment of employees.

Core Values

Regeneron's core values are deeply embedded in its day-to-day operations and company culture:

• Lead with Science: Science drives the business, and passion fuels the scientific endeavors. This involves supporting science at every level, from research to delivery.
• Take on Big Ideas: The company focuses on long-term goals, tackling significant challenges and bottlenecks to make a real difference.
• Make it Happen: Regeneron demonstrates a proactive approach to problem-solving, overcoming obstacles to achieve its goals.
• Be Great Together: Teamwork and collaboration are essential, fostering an environment where individuals bring out the best in each other.
• Do What's Right: The company acts with integrity, prioritizing ethical conduct towards employees, communities, patients, and the world.

These values collectively define 'The Regeneron Way,' shaping the behaviors and experiences within the company's unique community.

Financial Performance & Strategic Focus

Regeneron has demonstrated strong financial performance, which allows it to invest in future growth and return value to shareholders. In 2024, the company reported:

• Full year revenues increased by 8% to $14.20 billion compared to 2023. Excluding Ronapreve™, revenues increased by 10%.
• Fourth quarter revenues increased by 10% to $3.79 billion compared to the fourth quarter of 2023.
• Dupixent® global net sales (recorded by Sanofi) increased by 22% to $14.15 billion for the full year and by 15% to $3.70 billion for the fourth quarter.
• The company initiated a quarterly cash dividend program and increased its share repurchase capacity to approximately $4.5 billion.

Regeneron's strategic priorities include:

• Focusing on blockbuster medicines and advancing approximately 40 investigational candidates across various disease states.
• Deepening the impact of commercialized medicines, with ongoing leadership in retinal diseases, expanded global reach of Libtayo®, and growth from Dupixent®.
• Investing in research and development (R&D) to drive innovation and expand the clinical pipeline.

The company's commitment to R&D is evident in its financial investments. In 2024, Regeneron's R&D expenses were $5.132 billion, a 15.61% increase from $4.439 billion in 2023. This investment fuels the advancement of its clinical pipeline, including late-stage oncology programs, and supports higher headcount and related costs.

Regeneron's consistent financial growth is underpinned by its science-driven approach, patient-centric focus, and commitment to innovation. The company's mission, vision, and values align to create a culture that fosters scientific breakthroughs and delivers life-transforming medicines to patients worldwide.

Regeneron Pharmaceuticals, Inc. (REGN) Vision Statement of

Regeneron Pharmaceuticals, Inc. operates with a clearly defined mission, vision, and a set of core values that steer its strategic decisions and daily operations. These elements collectively reflect Regeneron's commitment to scientific innovation, patient care, and ethical conduct. Understanding these guiding principles provides insight into the company's goals, its approach to achieving them, and its dedication to its stakeholders.

Mission Statement

Regeneron's mission is to use the power of science to bring new medicines to patients. This is achieved through:

• Inventing: Discovering and developing innovative therapeutic candidates.
• Developing: Advancing these candidates through clinical trials.
• Manufacturing: Producing high-quality medicines.
• Commercializing: Making these medicines available to people with serious diseases.

In 2024, Regeneron invested $3.4 billion in research and development, underscoring its dedication to scientific innovation. This investment supported the advancement of numerous clinical programs and the discovery of new therapeutic targets.

Vision Statement

Regeneron's vision is to be a leading biotechnology company that:

• Invents life-transforming medicines for people with serious diseases.
• Continually innovates and improves upon its technologies.
• Is a great place to work, where talented people are inspired to do their best.
• Delivers value to its shareholders.

Regeneron's pipeline includes product candidates targeting a range of diseases, including cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Recent progress includes positive Phase 3 results for a novel therapy in a specific disease area, potentially addressing a significant unmet medical need. For example, the company's net product sales reached $12.21 billion in 2024, reflecting the impact of its medicines on patients' lives and its commercial success. Exploring Regeneron Pharmaceuticals, Inc. (REGN) Investor Profile: Who’s Buying and Why?

Core Values

Regeneron's core values are the fundamental beliefs upon which the company and its employees operate. These values include:

• Science-Driven: A commitment to rigorous scientific inquiry and data-driven decision-making.
• Integrity: Upholding the highest ethical standards in all activities.
• Excellence: Striving for the highest quality in everything they do.
• Teamwork: Working collaboratively to achieve common goals.
• Innovation: Encouraging creativity and the pursuit of novel solutions.

These values are reflected in Regeneron's consistent recognition as a top employer. For example, in 2024, Regeneron was recognized as one of the 'Best Companies to Work For' by Forbes, highlighting its commitment to creating a positive and productive work environment. Additionally, Regeneron actively engages in corporate social responsibility initiatives, contributing to communities and supporting STEM education programs.

Regeneron Pharmaceuticals, Inc. (REGN) Core Values of

Regeneron Pharmaceuticals, Inc. emphasizes a set of core values that guide its operations and interactions with the world. These values are central to its mission and contribute significantly to its approach to innovation, patient care, and corporate responsibility. Here’s an overview of these key principles:

Science-Driven Innovation

Regeneron places a strong emphasis on science as the foundation of its innovation. This commitment is reflected in its significant investment in research and development. In the fiscal year 2024, Regeneron allocated over 30% of its revenue to R&D, totaling approximately $3.5 billion. This investment fuels the discovery and development of new therapeutic solutions. The company's approach integrates cutting-edge technologies and a rigorous scientific process to advance medical science. For example, their work in genetics and antibody engineering has led to breakthroughs in treating various diseases. This dedication to scientific rigor ensures that Regeneron remains at the forefront of biotechnological advancements.

• R&D Investment: Over 30% of revenue, amounting to $3.5 billion in 2024.
• Technology Focus: Genetics and antibody engineering.

Uncompromising Ethics and Integrity

Regeneron is committed to maintaining the highest standards of ethics and integrity in all its activities. This commitment is evident in its corporate governance policies and compliance programs. The company ensures transparency and accountability in its operations, adhering strictly to both legal and ethical standards. For instance, Regeneron's compliance program includes regular audits and training sessions for employees to reinforce ethical conduct. This focus on integrity helps build trust with stakeholders, including patients, healthcare professionals, and investors. The company's dedication to ethical practices is a cornerstone of its reputation and long-term sustainability. Regeneron's ethical stance is further demonstrated by its consistent recognition in industry rankings for corporate responsibility.

• Compliance: Regular audits and employee training.
• Transparency: Strong corporate governance policies.

Focus on Patients

A core tenet of Regeneron's mission is a deep focus on patients. This commitment is reflected in the way the company develops and delivers its treatments. Regeneron actively engages with patient communities to understand their needs and challenges. For example, they partner with patient advocacy groups to provide support and resources. This patient-centric approach influences the design of clinical trials and the development of patient support programs. In 2024, Regeneron's patient assistance programs provided medications to thousands of eligible patients, ensuring access to critical treatments. This dedication to patients drives Regeneron's efforts to innovate and improve healthcare outcomes.

• Patient Engagement: Partnerships with patient advocacy groups.
• Assistance Programs: Provided medications to thousands of patients in 2024.

Teamwork and Collaboration

Regeneron fosters a culture of teamwork and collaboration, recognizing that collective expertise leads to better outcomes. This value is embedded in the company's organizational structure and daily operations. Cross-functional teams work together on research projects, bringing diverse perspectives and skills to the table. For example, scientists, engineers, and business professionals collaborate closely to develop and commercialize new products. Regeneron also collaborates with external partners, including academic institutions and other companies, to expand its research capabilities. This emphasis on teamwork promotes innovation and accelerates the development of new therapies. The collaborative environment at Regeneron is supported by open communication and mutual respect among team members.

• Cross-functional Teams: Collaboration among scientists, engineers, and business professionals.
• External Partnerships: Collaborations with academic institutions and other companies.

Continuous Improvement

Regeneron is dedicated to continuous improvement across all areas of its business. This commitment drives the company to constantly seek better ways to innovate, operate, and serve its stakeholders. Regeneron invests in training and development programs for its employees, encouraging them to enhance their skills and knowledge. The company also uses data analytics and performance metrics to identify areas for improvement. For example, Regeneron regularly reviews its manufacturing processes to increase efficiency and reduce costs. This focus on continuous improvement enables Regeneron to adapt to changing market conditions and maintain its competitive edge. The company's culture of learning and innovation supports its long-term success.

• Employee Development: Investments in training and development programs.
• Data Analytics: Use of performance metrics to identify areas for improvement.

Read more about Regeneron Pharmaceuticals, Inc. here: Exploring Regeneron Pharmaceuticals, Inc. (REGN) Investor Profile: Who’s Buying and Why?